Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P13236

UPID:
CCL4_HUMAN

ALTERNATIVE NAMES:
G-26 T-lymphocyte-secreted protein; HC21; Lymphocyte activation gene 1 protein; MIP-1-beta(1-69); Macrophage inflammatory protein 1-beta; PAT 744; Protein H400; SIS-gamma; Small-inducible cytokine A4; T-cell activation protein 2

ALTERNATIVE UPACC:
P13236; P22617; Q13704; Q3SXL8; Q6FGI8

BACKGROUND:
The protein C-C motif chemokine 4, with alternative names such as Macrophage inflammatory protein 1-beta and Lymphocyte activation gene 1 protein, is integral to the immune system's response to infection. It binds to the CCR5 receptor, playing a crucial role in the body's defense against HIV. Its ability to inhibit the entry of HIV-1 in T-cells by modulating the CCR5 receptor highlights its potential as a target for therapeutic intervention.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of C-C motif chemokine 4 offers promising avenues for developing new treatments for HIV and enhancing our understanding of immune response mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.